A Pragmatic Study of MRD-Guided Maintenance for Multiple Myeloma in Latin America
Applicability of MRD to Tailored Maintenance in Multiple Myeloma: A Pragmatic Prospective Multicenter Study in Latin America
This prospective, pragmatic, multicenter study aims to evaluate the clinical and quality-of-life outcomes of discontinuing maintenance therapy in newly diagnosed MM patients with sustained MRD negativity for two years. By implementing a structured active surveillance strategy with serial MRD and QoL assessments, this study seeks to determine whether treatment-free intervals can be safely achieved without compromising survival outcomes, while improving patient well-being and reducing financial burden.
If successful, this study will provide foundational evidence to support MRD-guided, individualized maintenance strategies in MM and will serve as a platform for future interventional trials in Latin America.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Multiple myeloma is a blood cancer that can require long-term maintenance treatment, even after a very good response to initial therapy. Although maintenance treatment can help control the disease, continuing it for many years may cause side effects, affect quality of life, and create financial burdens. Measurable residual disease (MRD) testing can detect very small amounts of myeloma cells that may remain after treatment.
This prospective, multicenter study in Latin America will evaluate a strategy of stopping maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved a complete or stringent complete response and have remained MRD-negative for at least two consecutive years while receiving maintenance therapy.
After maintenance therapy is discontinued, participants will be followed for 24 months through clinical assessments, MRD testing, and quality-of-life questionnaires every six months. Maintenance therapy will be restarted if MRD reappears or if clinical or biochemical criteria for disease relapse are met, according to the study protocol.
The main objective is to evaluate whether this strategy can be implemented safely and to measure the occurrence of MRD reappearance, disease relapse, or death within 24 months. Additional objectives include evaluating progression-free survival, overall survival, quality of life, time until maintenance therapy is restarted, and the feasibility of this approach across Latin American centers.
The study aims to generate evidence to help guide individualized maintenance treatment decisions for selected patients with multiple myeloma.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Yadith Karina Lopez Garcia, MD
- Telefonnummer: +52 81 8675 6718
- E-mail: yadith.lopezgrc@uanl.edu.mx
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age ≥18 years at the time of enrollment.
- Diagnosis of newly diagnosed multiple myeloma according to International Myeloma Working Group (IMWG) criteria.
- Achievement of complete response (CR) or stringent complete response (sCR) following first-line therapy, with or without autologous hematopoietic cell transplantation (auto-HCT).
- Receipt of maintenance therapy for a minimum of 12 months prior to screening.
- Sustained measurable residual disease (MRD) negativity documented by next-generation flow cytometry (NGF assay EuroFlow-based or equivalent): MRD negativity confirmed on at least two consecutive bone marrow assessments, separated by a minimum of 12 months, with assessments performed during ongoing maintenance therapy.
- Negative functional imaging prior to maintenance discontinuation, defined as no evidence of metabolically active focal lesions on PET/CT, performed during screening.
- Absence of extramedullary disease at the time of study entry.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Ability to comply with study procedures, including serial MRD and quality-of-life assessments.
- Provision of written informed consent prior to any study-specific procedures.
Exclusion Criteria:
- Evidence of MRD positivity by NGF at any assessment during screening.
- PET/CT-positive lesions suggestive of active myeloma at screening.
- Biochemical or clinical relapse at the time of screening, as defined by IMWG criteria.
- Prior progression while receiving maintenance therapy.
- Any uncontrolled medical condition or comorbidity that, in the investigator's judgment, would compromise patient safety or protocol compliance.
- Inability or unwillingness to adhere to protocol-defined follow-up and surveillance procedures.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: MRD-Guided Maintenance Discontinuation and Active Surveillance
Eligible participants will discontinue maintenance therapy after meeting the protocol-defined criteria, including sustained measurable residual disease (MRD) negativity for at least two consecutive years and no evidence of active disease on PET/CT. Participants will undergo active surveillance for 24 months, with clinical assessments, MRD testing, and health-related quality-of-life evaluations every six months. If MRD reappears or clinical or biochemical disease relapse criteria are met, maintenance therapy will be reinitiated according to the study protocol. All participants will receive the same intervention strategy, as this is a single-arm study. |
The intervention consists of discontinuing maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved complete response or stringent complete response and sustained measurable residual disease (MRD) negativity for at least two consecutive years during maintenance therapy, with no evidence of active disease on PET/CT. Following discontinuation, participants will undergo active surveillance for 24 months, with clinical assessments, bone marrow MRD testing, and health-related quality-of-life evaluations every six months. MRD will be assessed using next-generation flow cytometry. Maintenance therapy will be reinitiated if MRD reappears or if clinical or biochemical disease relapse criteria are met, according to the study protocol. The strategy is evaluated prospectively in a single-arm, multicenter study across Latin America. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Strategy Failure Rate at 24 Months Following MRD-Guided Maintenance Discontinuation
Tidsramme: From maintenance discontinuation (baseline) through 24 months.
|
Strategy failure is defined as the first occurrence of any of the following events after maintenance discontinuation: (1) measurable residual disease (MRD) resurgence, defined as conversion from sustained MRD negativity to MRD positivity detected by next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5); (2) clinical or biochemical relapse/progression according to IMWG criteria; or (3) death from any cause. The outcome will be measured as the proportion of participants experiencing at least one strategy failure event. |
From maintenance discontinuation (baseline) through 24 months.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Measurable Residual Disease-Free Survival (MRD-FS)
Tidsramme: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to the first occurrence of MRD resurgence or death from any cause. MRD will be assessed using next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5). MRD-FS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Treatment-Free Survival (TFS)
Tidsramme: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to re-initiation of maintenance therapy or death from any cause, whichever occurs first. TFS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Progression-Free Survival (PFS)
Tidsramme: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to documented clinical or biochemical disease progression according to IMWG criteria or death from any cause, whichever occurs first. PFS will be estimated using the Kaplan-Meier method. |
From maintenance discontinuation through 24 months.
|
|
Overall Survival (OS)
Tidsramme: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to death from any cause. Overall survival will be estimated using the Kaplan-Meier method, with survival probabilities reported at 12 and 24 months. |
From maintenance discontinuation through 24 months.
|
|
Measurable Residual Disease (MRD) Resurgence Rate
Tidsramme: At months 6, 12, 18, and 24 after maintenance discontinuation.
|
Proportion of participants who convert from sustained MRD negativity to MRD positivity during follow-up, assessed by next-generation flow cytometry (EuroFlow; sensitivity ≥10^-5). |
At months 6, 12, 18, and 24 after maintenance discontinuation.
|
|
Time to Maintenance Therapy Re-initiation
Tidsramme: From maintenance discontinuation through 24 months.
|
Time from maintenance discontinuation to the re-initiation of maintenance therapy, regardless of whether treatment is restarted due to MRD resurgence, clinical or biochemical relapse, or investigator discretion. |
From maintenance discontinuation through 24 months.
|
|
Change From Baseline in Health-Related Quality of Life Assessed by EORTC QLQ-C30
Tidsramme: Baseline and months 6, 12, 18, and 24.
|
Changes in health-related quality of life will be assessed using the EORTC QLQ-C30 questionnaire. |
Baseline and months 6, 12, 18, and 24.
|
|
Change From Baseline in Multiple Myeloma-Specific Quality of Life Assessed by EORTC QLQ-MY20
Tidsramme: Baseline and months 6, 12, 18, and 24.
|
Changes in multiple myeloma-specific health-related quality of life will be assessed using the EORTC QLQ-MY20 questionnaire. |
Baseline and months 6, 12, 18, and 24.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Neoplasmer
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Hæmatologiske sygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer, Plasmacelle
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Hæmoragiske lidelser
- Hemiske og lymfatiske sygdomme
- Myelomatose
- Sundhedstjenester Administration
- Sundhedskvalitet
- Resultatvurdering, sundhedsvæsen
- Resultat og procesvurdering, sundhedsvæsen
- Vågn venter
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HE26-00024
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .